Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:26 p.m. and Nov. 22, 2024, 7:26 p.m. from: Medical Devices And Equipment.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Document Date: Nov. 22, 2024, 2:15 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Document Extract: THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) - Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company") , a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $ 9.0 million prior to deducting underwriting discounts and commissions and offering expenses.
Document Source: https://www.globenewswire.com/news-release/2024/11/22/2986021/0/en/Autonomix-Medical-Inc-Announces-Pricing-of-9-0-Million-Underwritten-Public-Offering.html (archive.org page / archive.org listing)


SHL Medical announces plans to establish SHL Advantec

Document Date: Nov. 21, 2024, 9 a.m. / Source: PR Newswire
Activity Class: LocationActivity / Type: Added
Location_Added_By: Location: Document Extract: ZUG, Switzerland, Nov. 21, 2024 /PRNewswire/ - SHL Medical, a world leader in self-injection solutions, today announced plans to establish SHL Advantec - a dynamic sub-group dedicated to providing tooling and automation solutions to the healthcare sector and other industries.
Document Source: https://www.prnewswire.com/news-releases/shl-medical-announces-plans-to-establish-shl-advantec-302311854.html (archive.org page / archive.org listing)


SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment

Document Date: Nov. 21, 2024, 11 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: This collaboration aims to accelerate the development of advanced ceramic - based microspheres, a groundbreaking advancement in radiotherapeutic applications. The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R & D scale to pilot production. " Our successful manufacturing feasibility collaboration with NED Medical demonstrated that SINTX could manufacture novel ceramic - based microspheres containing the Yttrium-90 radioisotope that met NED Medical's preliminary specifications for a transarterial radioembolization (TARE) device for treatment of hepatocellular carcinoma. Further, these engineered microspheres contain porosity, allowing their future adaptation for targeted chemotherapy and combination therapies ," said Dr. Ryan Bock, CTO of SINTX Technologies. During this JDA, SINTX and NED Medical will collaborate closely, optimizing microsphere production, finalizing characterization and safety assessments, and producing microspheres needed to obtain pre-clinical data to be used as part of a device clearance submission.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985021/30038/en/SINTX-Technologies-and-NED-Medical-Partner-to-Advance-Cutting-Edge-Ceramic-Microsphere-Medical-Devices-for-Cancer-Treatment.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 7:58 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. " We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs™ Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs™ products in the U.S. and driving demand within the surgeon community", says Alan Donze, CEO of Bioretec Ltd. Further enquiries.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314027.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 7:58 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Bailiwick of Jersey
Partnership: Document Extract: TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB) , which is a distributor of medical and surgical products based in New Jersey. TSB is a leading medical solutions provider with 18 sales representatives dedicated to breaking the mold of traditional medical device distribution. Signing of the agreement will enable the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area covering one of the most populated areas of the United States. As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314027.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. " We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs™ Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs™ products in the U.S. and driving demand within the surgeon community", says Alan Donze, CEO of Bioretec Ltd. Further enquiries.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Bailiwick of Jersey
Partnership: Document Extract: TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB) , which is a distributor of medical and surgical products based in New Jersey. TSB is a leading medical solutions provider with 18 sales representatives dedicated to breaking the mold of traditional medical device distribution. Signing of the agreement will enable the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area covering one of the most populated areas of the United States. As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


Prestigious Cancer Center Institut Curie Introduces Ibex Medical Analytics' AI Tools for Cancer Diagnostics

Document Date: Nov. 21, 2024, 1:05 p.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Institut Curie continues their leadership in digital pathology adoption by implementing Ibex via their Sectra Digital Pathology Solution, providing an integrated workflow for pathologists to access Ibex's AI findings when reviewing cases. They are among the first academic laboratories in the world to utilize this recently released solution that ensures seamless diagnostic workflows. " The implementation of this tool in our department will allow our teams to save time, make our results more reliable, target areas of interest and improve the accuracy of our diagnoses ," says Professor Yves Allory, head of the pathology department at the Institut Curie, Saint-Cloud site, Professor at the University Versailles Saint Quentin. This deployment marks the latest chapter in the ongoing collaboration between the two organizations, which has already yielded groundbreaking advancements in AI-driven cancer diagnostics, including the validation of the Ibex Breast solution published in Nature's npj Breast Cancer. " We are honored to see our AI platform deployed in routine practice at such a prestigious institution as Institut Curie ," said Joseph Mossel, CEO of Ibex Medical Analytics.
Document Source: https://www.businesswire.com/news/home/20241121364639/en/Prestigious-Cancer-Center-Institut-Curie-Introduces-Ibex-Medical-Analytics%25E2%2580%2599-AI-Tools-for-Cancer-Diagnostics (archive.org page / archive.org listing)


Prestigious Cancer Center Institut Curie Introduces Ibex Medical Analytics' AI Tools for Cancer Diagnostics

Document Date: Nov. 21, 2024, 1:05 p.m. / Source: Business Wire
Activity Class: PartnershipActivity / Region: Republic of France
Partnership: Document Extract: Prestigious Cancer Center Institut Curie Introduces Ibex Medical Analytics' AI Tools for Cancer Diagnostics. Ibex Medical Analytics (Ibex) , the leader in AI-powered cancer diagnostics, and Institut Curie, France's globally renowned cancer center, today announced the introduction of Ibex's AI solution in routine clinical practice. Pathologists at Institut Curie are now using Ibex's AI tools when diagnosing prostate cancer to enhance accuracy, efficiency and improve patient outcomes; and plan to expand to a series of other Ibex applications in the coming months. " We 're excited to now use Ibex's AI technology in routine practice, further building upon our impressive research partnership. It's a team success between the Pathology team, the IT department, the data protection officer and the Information systems security managers" says Professor Anne Vincent-Salomon, head of the pathology department at Institut Curie, Professor at the University Paris-Sciences et Lettres.
Document Source: https://www.businesswire.com/news/home/20241121364639/en/Prestigious-Cancer-Center-Institut-Curie-Introduces-Ibex-Medical-Analytics%25E2%2580%2599-AI-Tools-for-Cancer-Diagnostics (archive.org page / archive.org listing)


Positron Corporation Partners With Upbeat Cardiology Solutions to Expand Cardiac PET-CT Offerings

Document Date: Nov. 21, 2024, 2:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: Niagara Falls
Partnership: Document Extract: With Positron's cutting-edge NeuSight PET-CT 64 Slice scanner at the core of these solutions, practices can offer the highest level of care, backed by a platform that combines clinical excellence with economic efficiency. Patrick O'Keefe, President of Upbeat Cardiology Solutions stated, "As a leader in innovation and turnkey solutions in the nuclear cardiology space we see our partnership with Positron as a step closer to our goal of bringing access of care to cardiology practices nationwide. Through this partnership we have another avenue to bring high end technologies into affordable camera lease and purchase options, overcoming a major cost obstacle and opening the door to cardiac practices of all sizes ." " Upbeat Cardiology Solutions excels in integrating advanced nuclear cardiology technology into practices and this collaboration is a strategic step forward in broadening access to our PET-CT technology and clinical services for all cardiology practices ," said Adel Abdullah, President of Positron Corporation. " Our NeuSight PET-CT 64 slice is an ideal solution to meet the rising demand for superior diagnostic tools in cardiac imaging.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985327/0/en/Positron-Corporation-Partners-With-Upbeat-Cardiology-Solutions-to-Expand-Cardiac-PET-CT-Offerings.html (archive.org page / archive.org listing)


Smart ring maker Oura picks up $75M series D, inks strategic partnership with Dexcom

Document Date: Nov. 19, 2024, 11 a.m. / Source: Fierce Healthcare
Activity Class: PartnershipActivity
Partnership: Document Extract: Smart ring maker Oura picks up $ 75M series D, inks strategic partnership with Dexcom. Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. Oura also picked up $ 75 million from Dexcom in a series D funding round, valuing the company at more than $ 5 billion, the company announced Tuesday. The company, which launched out of Finland as a sleep tracking smart ring in 2015, has now sold 2.5 million rings. It expects to see annual sales double in 2024 to roughly $ 500 million, and the company is profitable, according to Oura CEO Tom Hale.
Document Source: https://www.fiercehealthcare.com/digital-health/smart-ring-maker-oura-picks-75m-series-d-inks-strategic-partnership-dexcom (archive.org page / archive.org listing)


SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

Document Date: Nov. 19, 2024, 11 a.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983389/30038/en/SINTX-Technologies-Appoints-Gregg-R-Honigblum-as-Chief-Strategy-Officer.html (archive.org page / archive.org listing)


SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

Document Date: Nov. 19, 2024, 11 a.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting / Region: Salt Lake City
Role: Person: Organization: Document Extract: Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company") , an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO) .
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983389/30038/en/SINTX-Technologies-Appoints-Gregg-R-Honigblum-as-Chief-Strategy-Officer.html (archive.org page / archive.org listing)


Erica Rogers Joins the Board of Directors at Axena Health, Bringing Proven Commercial Leadership and Expertise in Groundbreaking Healthcare Solutions

Document Date: Nov. 19, 2024, 1:30 p.m. / Source: Business Wire
Activity Class: RoleActivity / Type: Starting / Region: United States
Role: Person: Organization: Document Extract: Axena Health, Inc. (Axena Health) , a medical device company focused on female pelvic health, today announced the appointment of Erica Rogers to its Board of Directors.
Document Source: https://www.businesswire.com/news/home/20241119812886/en/Erica-Rogers-Joins-the-Board-of-Directors-at-Axena-Health-Bringing-Proven-Commercial-Leadership-and-Expertise-in-Groundbreaking-Healthcare-Solutions (archive.org page / archive.org listing)


MIT Sloan Professor Steven Eppinger Joins SurgiBox's Board of Directors

Document Date: Nov. 22, 2024, 1:17 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Cambridge, United States
Role: Person: Organization: Document Extract: MIT Sloan Professor Steven Eppinger Joins SurgiBox's Board of Directors.
Document Source: https://www.prnewswire.com/news-releases/mit-sloan-professor-steven-eppinger-joins-surgiboxs-board-of-directors-302313037.html (archive.org page / archive.org listing)


AdvaMed Statement on President-elect Trump's Intent to Nominate Dr. Oz to Lead CMS

Document Date: Nov. 19, 2024, 11:25 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Washington
Role: Person: Organization: Document Extract: WASHINGTON, Nov. 19, 2024 /PRNewswire/ - AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on President-elect Trump's announcement that he intends to nominate Dr. Mehmet Oz to serve as Administrator of the Centers for Medicare & Medicaid Services:
Document Source: https://www.prnewswire.com/news-releases/advamed-statement-on-president-elect-trumps-intent-to-nominate-dr-oz-to-lead-cms-302310683.html (archive.org page / archive.org listing)


Caris Life Sciences Announces Appointment of Dr. Jeffrey Vacirca to Board of Directors

Document Date: Nov. 21, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: United States, Texas
Role: Person: Organization: Document Extract: IRVING, Texas, Nov. 21, 2024 /PRNewswire/ - Caris Life Sciences® (Caris) , a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announces that Jeffrey Vacirca, MD, FACP, has joined the Caris Board of Directors, effective November 7, 2024.
Document Source: https://www.prnewswire.com/news-releases/caris-life-sciences-announces-appointment-of-dr-jeffrey-vacirca-to-board-of-directors-302312372.html (archive.org page / archive.org listing)


Surendralal Karsanbhai Elected to Merck Board of Directors

Document Date: Nov. 22, 2024, 11:30 a.m. / Source: Business Wire
Activity Class: RoleActivity / Type: Starting / Region: Canada, United States
Role: Person: Organization: Document Extract: Merck (NYSE: MRK) , known as MSD outside of the United States and Canada, today announced that Surendralal L. "Lal" Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR) , will join Merck's board of directors effective January 1, 2025.
Document Source: https://www.businesswire.com/news/home/20241122809362/en/Surendralal-Karsanbhai-Elected-to-Merck-Board-of-Directors (archive.org page / archive.org listing)


Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

Document Date: Nov. 19, 2024, 1 p.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting / Region: Sunnyvale
Role: Person: Organization: Document Extract: SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) , a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell") , today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983528/0/en/Ceribell-Appoints-Kristie-Rodenbush-as-Chief-People-Officer-and-Brian-Price-as-Senior-Vice-President-of-Marketing.html (archive.org page / archive.org listing)


Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

Document Date: Nov. 19, 2024, 1 p.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting / Region: Sunnyvale
Role: Person: Organization: Document Extract: SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) , a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell") , today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983528/0/en/Ceribell-Appoints-Kristie-Rodenbush-as-Chief-People-Officer-and-Brian-Price-as-Senior-Vice-President-of-Marketing.html (archive.org page / archive.org listing)


Vantage MedTech Appoints Kimberly Subrahmanyan as PMO and Engineering Services Leader

Document Date: Nov. 19, 2024, 2:14 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: Vantage MedTech Appoints Kimberly Subrahmanyan as PMO and Engineering Services Leader.
Document Source: https://www.prnewswire.com/news-releases/vantage-medtech-appoints-kimberly-subrahmanyan-as-pmo-and-engineering-services-leader-302309101.html (archive.org page / archive.org listing)


Vantage MedTech Appoints Kimberly Subrahmanyan as PMO and Engineering Services Leader

Document Date: Nov. 19, 2024, 2:14 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Kansas
Role: Person: Organization: Document Extract: LENEXA, Kan. and MOONACHIE, N.J., Nov. 19, 2024 /PRNewswire/ - Vantage MedTech, a leading provider of comprehensive design and manufacturing services for medical technology, today announced that Kimberly Subrahmanyan has joined the company's leadership team as Sr. Vice President of Technical Services and Program Management.
Document Source: https://www.prnewswire.com/news-releases/vantage-medtech-appoints-kimberly-subrahmanyan-as-pmo-and-engineering-services-leader-302309101.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.